Просмотры

Аннотация: 991

PDF (Английский): 329

Cited-by

1. Movahedan M., Ellis U.M., Barry A.R. Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients with Heterozygous Familial Hypercholesterolemia: A Meta-analysis // American Journal of Cardiovascular Drugs. - 2025. - Т. 25. - №1. - С. 47. doi: 10.1007/s40256-024-00682-0
2. Singh R., Chandi S.K., Sran S., и др. Emerging Therapeutic Strategies in Cardiovascular Diseases // Cureus. - 2024. doi: 10.7759/cureus.64388
3. Preta G. Development of New Genome Editing Tools for the Treatment of Hyperlipidemia // Cells. - 2023. - Т. 12. - №20. - С. 2466. doi: 10.3390/cells12202466
4. Xiao G., Gao S., Xie Y., и др. Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis // Medicina. - 2024. - Т. 60. - №10. - С. 1646. doi: 10.3390/medicina60101646
5. Jiang Y., Wang Y., Ma S., и др. Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis // Frontiers in Cardiovascular Medicine. - 2025. - Т. 11. doi: 10.3389/fcvm.2024.1415668
6. Mijnster R.J., Mulder J.W., Galema-Boers A.M., и др. Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registry // Atherosclerosis. - 2025. - С. 120229. doi: 10.1016/j.atherosclerosis.2025.120229
7. Abduljabbar M.H. PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression // Pharmaceuticals. - 2024. - Т. 17. - №12. - С. 1581. doi: 10.3390/ph17121581
8. Nejabat M., Hadizadeh F., Almahmeed W., Sahebkar A. Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases // Drug Discovery Today. - 2025. - Т. 30. - №3. - С. 104316. doi: 10.1016/j.drudis.2025.104316
9. Kroemer G., Maier A.B., Cuervo A.M., и др. From geroscience to precision geromedicine: Understanding and managing aging // Cell. - 2025. - Т. 188. - №8. - С. 2043. doi: 10.1016/j.cell.2025.03.011